secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001193125-24-274871
Event type: debt
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio prices $100M public offering at $3/sh and restructures $505M Nant Capital note
--------------------------------------------------------------------------------

- Public offering of 33.3M shares at $3/sh for gross proceeds ~$100M; net to company ~$93.1M from firm shares.
- Underwriters have 30-day option to purchase additional 5M shares at $3/sh; potential net proceeds $107.2M.
- Concurrent debt restructuring: Nant Capital notes consolidated into $505M note due Dec 2027, interest SOFR+8%, convertible at $5.427/sh.
- Limited consent from Oberland Capital (RIPA) obtained for the debt restructuring.
- Net proceeds intended for ANKTIVA commercialization, BCG-naïve NMIBC and NSCLC trials, R&D, working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312524274871/0001193125-24-274871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312524274871/d875134d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-274871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer